

# 1 Preclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in

## 2 glioblastoma

3

4 Anthony Waked<sup>1,2</sup>, [Melissa Crabbé<sup>1</sup>](#), [Virginie Neirlinckx<sup>2</sup>](#), [Sunay Rodriguez Pérez<sup>1</sup>](#), [Jasmien Wellens<sup>1</sup>](#),

5 [Bernard Rogister<sup>2,3</sup>](#), [M. Abderrafi Benotmane<sup>1</sup>](#), [Koen Vermeulen<sup>1\\*</sup>](#)

6 <sup>1</sup>*Nuclear Medical Application Institute, Belgian Nuclear Research Centre (SCK CEN), Mol, Belgium*

7 <sup>2</sup>*Laboratory of Nervous System Disorders and Therapy, GIGA Neurosciences, Université de Liège, Liège, Belgium*

8 <sup>3</sup>*Neurology Department, CHU Liège, Belgium.*

9

10 **\*Corresponding author:**

11 Koen Vermeulen

12 [koen.vermeulen@sckcen.be](mailto:koen.vermeulen@sckcen.be)

13 Nuclear Medical Application Institute, Belgian Nuclear Research Centre (SCK CEN), Mol, Belgium